

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01   Amended 01/01/11

<b>Name of entity</b>	Paradigm Biopharmaceuticals Limited
<b>ABN</b>	94 169 346 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Paul Rennie
<b>Date of last notice</b>	30 December 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	(1) Direct (2) Indirect (3) Indirect (4) Indirect (5) Direct (6) Indirect
<b>Nature of indirect interest (including registered holder)</b>	(1) N/A (2) SMSF (3) FT (4) SMSF (5) N/A (6) SMSF
<b>Date of change</b>	(1) 11 February 2025 (2) 11 February 2025 (3) 11 February 2025 (4) N/A (5) 11 February 2025 (6) 11 February 2025

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>No. of securities held prior to change</b>	(1) 200,000 - FULLY PAID ORDINARY SHARES (2) 10,767,843 - FULLY PAID ORDINARY SHARES (3) 600,000 - FULLY PAID ORDINARY SHARES (4) 1,700,000 - PERFORMANCE RIGHTS EXP 20/12/2027 (5) 8,545,848 - FULLY PAID ORDINARY SHARES (6) 613,059 - FULLY PAID ORDINARY SHARES
<b>Class</b>	(1) FULLY PAID ORDINARY SHARES (2) FULLY PAID ORDINARY SHARES (3) FULLY PAID ORDINARY SHARES (4) PERFORMANCE RIGHTS EXP 20/12/2027 (5) FULLY PAID ORDINARY SHARES (6) FULLY PAID ORDINARY SHARES
<b>Number acquired</b>	(1) 50,000 OPTIONS EXPIRING 11-FEB-2026 (2) 2,691,961 OPTIONS EXPIRING 11-FEB-2026 (3) 150,000 OPTIONS EXPIRING 11-FEB-2026 (4) NIL (5) 2,136,462 OPTIONS EXPIRING 11-FEB-2026 (6) 153,265 OPTIONS EXPIRING 11-FEB-2026
<b>Number disposed</b>	(1) NIL (2) NIL (3) NIL (4) NIL (5) NIL (6) NIL
<b>Value/Consideration</b>	(1) N/A (2) N/A (3) N/A (4) N/A (5) N/A (6) N/A

<b>No. of securities held after change</b>	(1) 200,000 - FULLY PAID ORDINARY SHARES 50,000 - OPTIONS EXPIRING 11-FEB-2026  (2) 10,767,843 - FULLY PAID ORDINARY SHARES 2,691,961 - OPTIONS EXPIRING 11-FEB-2026  (3) 600,000 - FULLY PAID ORDINARY SHARES 150,000 - OPTIONS EXPIRING 11-FEB-2026  (4) 1,700,000 - PERFORMANCE RIGHTS EXP 20/12/2027  (5) 8,545,848 - FULLY PAID ORDINARY SHARES 2,136,462 - OPTIONS EXPIRING 11-FEB-2026  (6) 613,059 - FULLY PAID ORDINARY SHARES 153,265 - OPTIONS EXPIRING 11-FEB-2026
<b>Nature of change</b>	(1) Loyalty Options Offer  (2) Loyalty Options Offer  (3) Loyalty Options Offer  (4) N/A  (5) Loyalty Options Offer  (6) Loyalty Options Offer

## Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b>	N/A
<b>Interest after change</b>	N/A

## Part 3 - <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.